Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • ImmunoGen (IMGN) Announces Presentation of Positive Anti-cancer Therapy Product 0 comments
    Nov 19, 2010 6:32 PM | about stocks: IMGN
    ImmunoGen Inc., a developer of anti-cancer products using its Targeted Antibody Payload (NYSE:TAP) technology, today announced the presentation of positive clinical data for its IMGN388 anti-cancer compound at the 22nc EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

    IMGN388 is designed to target and kill cells that express its αv integrin target. The company said this antigen is found on various types of solid tumors, including lung, breast and prostate cancers, as well as on vascular cells in the process of forming new blood vessels, a process that needs to occur for any solid tumor to grow.

    The company’s study demonstrates that IMGN388 was well-tolerated, and the company organized a poster presentation, entitled “A Phase I Study of IMGN388, an Antibody Drug Conjugate Targeting αv Integrin, in Patients with Solid Tumors” for the symposium.

    The presentation explains that findings from IMGN388’s dose-finding phase, which was designed to determine the maximum tolerated dose of the compound when administered once every three weeks, was found to be well tolerated at certain doses.

    “IMGN388 was well tolerated at doses at which evidence of anticancer activity was observed,” James O’Leary, MD, vice president and chief medical officer of ImmunoGen stated in the press release. “Based on the tolerability of the compound and its pharmacokinetic profile, our next step will be to evaluate IMGN388 when administered on a more frequent basis.”

    For more information visit immunogen.com

    Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net



    Disclosure: no positions
    Stocks: IMGN
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.